Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
14.69
USD
|
+2.08%
|
|
-1.41%
|
-53.28%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
248.9
|
377.7
|
654.4
|
317.2
|
-
|
-
|
Enterprise Value (EV)
1 |
106.8
|
278.3
|
593.1
|
280.1
|
304.6
|
316
|
P/E ratio
|
-2.94
x
|
-9.08
x
|
-15.8
x
|
-7.51
x
|
-9.45
x
|
-17.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.1
x
|
16.8
x
|
16.7
x
|
5.78
x
|
4.13
x
|
2.85
x
|
EV / Revenue
|
8.2
x
|
12.4
x
|
15.1
x
|
5.1
x
|
3.97
x
|
2.84
x
|
EV / EBITDA
|
-4.14
x
|
-6.61
x
|
-16.3
x
|
-7.34
x
|
-10.1
x
|
-15.1
x
|
EV / FCF
|
-3.69
x
|
-6.42
x
|
-15
x
|
-9.66
x
|
-15.2
x
|
-45.1
x
|
FCF Yield
|
-27.1%
|
-15.6%
|
-6.68%
|
-10.4%
|
-6.57%
|
-2.22%
|
Price to Book
|
1.71
x
|
3.47
x
|
8.64
x
|
5.65
x
|
8.74
x
|
10.1
x
|
Nbr of stocks (in thousands)
|
20,352
|
20,584
|
20,816
|
21,595
|
-
|
-
|
Reference price
2 |
12.23
|
18.35
|
31.44
|
14.69
|
14.69
|
14.69
|
Announcement Date
|
2/15/22
|
1/26/23
|
1/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
13.04
|
22.47
|
39.3
|
54.89
|
76.74
|
111.4
|
EBITDA
1 |
-
|
-25.8
|
-42.12
|
-36.28
|
-38.16
|
-30.13
|
-20.93
|
EBIT
1 |
-
|
-25.97
|
-42.53
|
-43.1
|
-41.73
|
-33.35
|
-18.95
|
Operating Margin
|
-
|
-199.2%
|
-189.27%
|
-109.69%
|
-76.03%
|
-43.45%
|
-17%
|
Earnings before Tax (EBT)
1 |
-
|
-42.99
|
-41.32
|
-41.05
|
-42.41
|
-34.44
|
-20.48
|
Net income
1 |
-14.11
|
-43.08
|
-41.43
|
-41.2
|
-41.93
|
-34.4
|
-20.57
|
Net margin
|
-
|
-330.45%
|
-184.38%
|
-104.85%
|
-76.38%
|
-44.82%
|
-18.47%
|
EPS
2 |
-37.18
|
-4.160
|
-2.020
|
-1.990
|
-1.957
|
-1.555
|
-0.8565
|
Free Cash Flow
1 |
-
|
-28.92
|
-43.36
|
-39.61
|
-29
|
-20
|
-7
|
FCF margin
|
-
|
-221.81%
|
-192.99%
|
-100.81%
|
-52.83%
|
-26.06%
|
-6.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/9/21
|
2/15/22
|
1/26/23
|
1/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.395
|
3.658
|
4.076
|
5.031
|
6.186
|
7.176
|
7.979
|
9.5
|
10.51
|
11.3
|
11.37
|
13
|
14.56
|
15.95
|
16.41
|
EBITDA
1 |
-7.249
|
-8.732
|
-9.846
|
-10.92
|
-9.999
|
-11.35
|
-10.33
|
-10.15
|
-7.859
|
-7.942
|
-10.55
|
-10.04
|
-8.676
|
-9.052
|
-4.623
|
EBIT
1 |
-7.291
|
-8.788
|
-9.908
|
-11.01
|
-10.13
|
-11.48
|
-12.16
|
-11.75
|
-9.528
|
-9.661
|
-11.4
|
-10.87
|
-10.14
|
-9.699
|
-5.713
|
Operating Margin
|
-214.76%
|
-240.24%
|
-243.08%
|
-218.92%
|
-163.69%
|
-159.96%
|
-152.43%
|
-123.71%
|
-90.65%
|
-85.46%
|
-100.25%
|
-83.59%
|
-69.59%
|
-60.82%
|
-34.81%
|
Earnings before Tax (EBT)
1 |
-6.11
|
-10.54
|
-9.965
|
-11.05
|
-9.798
|
-10.51
|
-11.34
|
-11.62
|
-8.971
|
-9.124
|
-11.36
|
-11.08
|
-10.09
|
-9.656
|
-5.841
|
Net income
1 |
-6.133
|
-10.57
|
-9.991
|
-11.07
|
-9.83
|
-10.54
|
-11.37
|
-11.65
|
-9.011
|
-9.163
|
-11.37
|
-11.09
|
-10.13
|
-9.665
|
-5.864
|
Net margin
|
-180.65%
|
-288.96%
|
-245.12%
|
-220.06%
|
-158.91%
|
-146.82%
|
-142.51%
|
-122.64%
|
-85.73%
|
-81.05%
|
-99.96%
|
-85.26%
|
-69.53%
|
-60.61%
|
-35.73%
|
EPS
2 |
-0.3000
|
-0.5200
|
-0.4900
|
-0.5400
|
-0.4800
|
-0.5100
|
-0.5500
|
-0.5600
|
-0.4300
|
-0.4400
|
-0.5394
|
-0.5013
|
-0.4680
|
-0.4502
|
-0.3500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/15/22
|
4/25/22
|
7/28/22
|
11/1/22
|
1/26/23
|
4/27/23
|
7/25/23
|
10/26/23
|
1/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
142
|
99.4
|
61.3
|
37.1
|
12.7
|
1.21
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-28.9
|
-43.4
|
-39.6
|
-29
|
-20
|
-7
|
ROE (net income / shareholders' equity)
|
-
|
-47.2%
|
-32.5%
|
-44.5%
|
-63.9%
|
-92.6%
|
-99.5%
|
ROA (Net income/ Total Assets)
|
-
|
-39.6%
|
-29.9%
|
-34.3%
|
-50.6%
|
-63.5%
|
-50.1%
|
Assets
1 |
-
|
108.7
|
138.7
|
120.1
|
82.94
|
54.14
|
41.1
|
Book Value Per Share
2 |
-
|
7.160
|
5.290
|
3.640
|
2.600
|
1.680
|
1.450
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.18
|
0.69
|
0.59
|
1
|
1
|
1
|
Capex / Sales
|
-
|
9.07%
|
3.05%
|
1.5%
|
1.82%
|
1.3%
|
0.9%
|
Announcement Date
|
4/9/21
|
2/15/22
|
1/26/23
|
1/25/24
|
-
|
-
|
-
|
Last Close Price
14.69
USD Average target price
34
USD Spread / Average Target +131.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -53.28% | 317M | | +73.17% | 12.38B | | -18.74% | 7.92B | | +16.15% | 7.2B | | +4.81% | 5.84B | | +5.99% | 5.01B | | +27.07% | 4.53B | | -21.67% | 3.88B | | -40.82% | 2.23B | | +1.49% | 2.02B |
Medical Equipment
|